While complete cure was achieved in CD200R-/- mice with this regimen, in CD200-/- mice the same protocol was able to decrease EMT6 metastasis, but was insufficient for generating a long-lasting anti-tumor immune response [5]. This evidence concerns the gene CD200 and neoplasm.